These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 1347468)

  • 1. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Giaffer MH; O'Brien CJ; Holdsworth CD
    Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
    Rao SS; Cann PA; Holdsworth CD
    Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N; Weir DG; Kelleher D
    Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides.
    Turunen U; Elomaa I; Anttila VJ; Seppälä K
    Scand J Gastroenterol; 1987 Sep; 22(7):798-802. PubMed ID: 2890198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
    Birketvedt GS; Berg KJ; Fausa O; Florholmen J
    Inflamm Bowel Dis; 2000 Nov; 6(4):275-9. PubMed ID: 11149559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
    Donald IP; Wilkinson SP
    Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Brogden RN; Sorkin EM
    Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesalazine in childhood inflammatory bowel disease.
    Barden L; Lipson A; Pert P; Walker-Smith JA
    Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesalazine: a global safety evaluation.
    Brimblecombe R
    Scand J Gastroenterol Suppl; 1990; 172():66. PubMed ID: 1972297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1992 Oct; 27(10):863-8. PubMed ID: 1359629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
    Rutgeerts P
    Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.
    Rijk MC; van Hogezand RA; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1989 Dec; 24(10):1179-85. PubMed ID: 2574905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
    Ransford RA; Langman MJ
    Gut; 2002 Oct; 51(4):536-9. PubMed ID: 12235076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of stress-induced gastric ulcers by sulphasalazine and its constituents (sulphapyridine and 5-aminosalicylic acid) in rats.
    Garg GP; Cho CH; Ogle CW
    Pharmacology; 1990; 40(6):318-24. PubMed ID: 1978355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olsalazine in patients intolerant of sulphasalazine.
    Ireland A; Jewell DP
    Scand J Gastroenterol; 1987 Nov; 22(9):1038-40. PubMed ID: 2892247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.